Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A standard regimen of dexamethasone in comparison to two dex-sparing regimens in addition to NEPA in preventing CINV in naive NSCLC patients to be treated with cisplatin based chemotherapy: a three-arm, open-label, randomized study

Next Previous
Search
Trial Profile

A standard regimen of dexamethasone in comparison to two dex-sparing regimens in addition to NEPA in preventing CINV in naive NSCLC patients to be treated with cisplatin based chemotherapy: a three-arm, open-label, randomized study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netupitant/palonosetron (Primary) ; Dexamethasone; Dexamethasone; Dexamethasone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LUNG-NEPA

    • Most Recent Events

    • 06 Sep 2022 Status changed from active, no longer recruiting to completed, as per European Clinical Trials Database record
    • 24 Aug 2022 Results assessing the impact of emesis on daily lives of patients receiving DEX-sparing regimens using the Functional Living Index-Emesis, published in the BMC Cancer
    • 01 Oct 2021 Results published in the Oncologist

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top